Edith Conlon, a 58-year-old mother of three, has been diagnosed with cancer three times, with the latest recurrence being particularly aggressive. Despite her resilience and determination, the NHS's refusal to provide her with the novel drug Enhertu, which could offer a viable alternative to traditional chemotherapy, has left her family in a dire financial situation. The drug, which costs around £8,000 per month, is currently available in Scotland and 18 other European countries, but not in England and Wales under the NHS.
Maria Conlon, Edith's daughter, has launched an online fundraiser to pay for her mother's private treatment. She emphasizes the emotional rollercoaster the family has endured due to the NHS's inability to provide Enhertu, which offers better survival rates and treatment options. Maria's efforts to raise awareness and funds are not only a testament to her love and dedication but also highlight the absurdity of arguing over the price of a life-saving drug.
The family's situation underscores the importance of accessibility to innovative cancer treatments. While Maria's fundraiser aims to provide immediate relief, the long-term goal is to make Enhertu publicly available on the NHS for all women who need it. This case serves as a stark reminder of the human cost of healthcare policies and the need for a more compassionate and equitable approach to cancer treatment.
